通过使用两种作用方式不同的药物降低Cdk5水平来潜在治愈阿尔茨海默病。
Potential cure of Alzheimer's disease by reducing the level of Cdk5 using two drugs, each with a different modus operandi.
作者信息
Fessel Jeffrey
机构信息
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
出版信息
J Alzheimers Dis Rep. 2025 Apr 15;9:25424823251335870. doi: 10.1177/25424823251335870. eCollection 2025 Jan-Dec.
Abstract
There is need to understand the direct cause and, therefore, the appropriate treatment, of Alzheimer's disease (AD). A Google search was used to discern a) the primary cause of AD, and b) its treatment. Activation of Cdk5 is the primary cause for AD. Activation of Cdk5 may be decreased by using two drugs, roscovitine and tamoxifen, each having a different mechanism of action. Clinical trials should validate the efficacy and safety of using roscovitine and tamoxifen.
摘要
有必要了解阿尔茨海默病（AD）的直接病因以及相应的治疗方法。通过谷歌搜索来确定：a）AD的主要病因，以及b）其治疗方法。细胞周期蛋白依赖性激酶5（Cdk5）的激活是AD的主要病因。使用两种药物——罗可辛（roscovitine）和他莫昔芬（tamoxifen）可降低Cdk5的激活，这两种药物的作用机制不同。临床试验应验证使用罗可辛和他莫昔芬的疗效和安全性。
相似文献
1
Potential cure of Alzheimer's disease by reducing the level of Cdk5 using two drugs, each with a different modus operandi.通过使用两种作用方式不同的药物降低Cdk5水平来潜在治愈阿尔茨海默病。
J Alzheimers Dis Rep. 2025 Apr 15;9:25424823251335870. doi: 10.1177/25424823251335870. eCollection 2025 Jan-Dec.
2
Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction.萝卜硫素，一种CDK5抑制剂，通过减少β淀粉样蛋白沉积、tau蛋白过度磷酸化和突触功能障碍，减轻阿尔茨海默病转基因小鼠模型的认知缺陷。
Int Immunopharmacol. 2023 Jan;114:109504. doi: 10.1016/j.intimp.2022.109504. Epub 2022 Dec 9.
3
Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins.cdk5/p25 在 N2a 细胞中的表达增加导致神经丝蛋白的过度磷酸化和轴突运输受损。
Life Sci. 2010 Mar 27;86(13-14):532-7. doi: 10.1016/j.lfs.2010.02.009. Epub 2010 Feb 12.
4
Ginsenoside Rg1 reduces β‑amyloid levels by inhibiting CDΚ5‑induced PPARγ phosphorylation in a neuron model of Alzheimer's disease.人参皂苷 Rg1 通过抑制阿尔茨海默病神经元模型中 CDΚ5 诱导的 PPARγ 磷酸化来降低 β‑淀粉样蛋白水平。
Mol Med Rep. 2020 Oct;22(4):3277-3288. doi: 10.3892/mmr.2020.11424. Epub 2020 Aug 7.
5
Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity.抑制细胞周期蛋白依赖性激酶 5 会影响淀粉样β毒性的小鼠模型中的早期神经炎症信号转导。
J Neuroinflammation. 2018 Jan 4;15(1):1. doi: 10.1186/s12974-017-1027-y.
6
Divergent roles of GSK3 and CDK5 in APP processing.糖原合成酶激酶3（GSK3）和周期蛋白依赖性激酶5（CDK5）在淀粉样前体蛋白（APP）加工中的不同作用
Biochem Biophys Res Commun. 2003 Dec 26;312(4):922-9. doi: 10.1016/j.bbrc.2003.11.014.
7
Cdk5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease.Cdk5 蛋白抑制和 Aβ42 通过转录后机制增加原代神经元中的 BACE1 蛋白水平：CDK5 作为阿尔茨海默病治疗靶点的意义。
J Biol Chem. 2012 Mar 2;287(10):7224-35. doi: 10.1074/jbc.M111.333914. Epub 2012 Jan 5.
8
Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease.调节异常的 CDK5 信号可挽救阿尔茨海默病模型中受损的神经发生。
Cell Death Dis. 2011 Feb 10;2(2):e120. doi: 10.1038/cddis.2011.2.
9
Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease.细胞周期蛋白依赖性激酶5：阿尔茨海默病的一条新途径。
Brain Res Bull. 2017 Jun;132:28-38. doi: 10.1016/j.brainresbull.2017.05.006. Epub 2017 May 17.
10
Identification of Novel Compounds Inhibiting the Kinase Activity of the CDK5/p25 Complex via Direct Binding to p25.
Biochemistry. 2023 May 2;62(9):1452-1463. doi: 10.1021/acs.biochem.2c00691. Epub 2023 Apr 19.
本文引用的文献
1
Tamoxifen in men: a review of adverse events.他莫昔芬在男性中的应用：不良事件综述
Andrology. 2016 Sep;4(5):776-88. doi: 10.1111/andr.12197. Epub 2016 May 6.
2
Neuroprotective Mechanisms Mediated by CDK5 Inhibition.CDK5抑制介导的神经保护机制。
Curr Pharm Des. 2016;22(5):527-34. doi: 10.2174/1381612822666151124235028.
3
Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.他莫昔芬通过与p35/p25相互作用抑制CDK5激酶活性，并调节tau蛋白的磷酸化模式。
Chem Biol. 2015 Apr 23;22(4):472-482. doi: 10.1016/j.chembiol.2015.03.009. Epub 2015 Apr 9.
4
A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.p35 是一种 Cdk5 的激活剂，其截短肽能预防模型鼠的阿尔茨海默病表型。
FASEB J. 2013 Jan;27(1):174-86. doi: 10.1096/fj.12-217497. Epub 2012 Oct 4.
5
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.系统给予（S）-罗克洛文延迟治疗可提供神经保护作用，并抑制动物中风模型中 CDK5 活性的增加。
PLoS One. 2010 Aug 12;5(8):e12117. doi: 10.1371/journal.pone.0012117.
6
Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.源自细胞周期蛋白依赖性激酶5激活剂p35的肽，可特异性抑制细胞周期蛋白依赖性激酶5的失调活性。
Biotechnol J. 2007 Aug;2(8):978-87. doi: 10.1002/biot.200700057.
7
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.比卡鲁胺所致男性乳房发育症和乳房疼痛的预防与管理：他莫昔芬和阿那曲唑的随机内分泌学及临床研究
Prostate Cancer Prostatic Dis. 2005;8(1):75-83. doi: 10.1038/sj.pcan.4500782.
8
Cdk5 deregulation in the pathogenesis of Alzheimer's disease.Cdk5失调在阿尔茨海默病发病机制中的作用
Trends Mol Med. 2004 Sep;10(9):452-8. doi: 10.1016/j.molmed.2004.07.001.
9
Treatment of gynecomastia with tamoxifen: a double-blind crossover study.他莫昔芬治疗男性乳房发育症：一项双盲交叉研究。
Metabolism. 1986 Aug;35(8):705-8. doi: 10.1016/0026-0495(86)90237-4.
Zotero 插件